Although results from this survival analysis should be interpreted with caution given the mere exploratory nature, they appear consistent with available scattered retrospective data supporting a possible negative prognostic impact of HER2-low expression in early breast cancer patients24,27–29, especially when considering the HR-positive subset28. Here, ERBB2 is linked to breast cancer.